| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | BPIFA2 |
| Uniprot No | Q96DR5 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 19-249aa |
| 氨基酸序列 | ESLLDNLGNDLSNVVDKLEPVLHEGLETVDNTLKGILEKLKVDLGVLQKSSAWQLAKQKAQEAEKLLNNVISKLLPTNTDIFGLKISNSLILDVKAEPIDDGKGLNLSFPVTANVTVAGPIIGQIINLKASLDLLTAVTIETDPQTHQPVAVLGECASDPTSISLSLLDKHSQIINKFVNSVINTLKSTVSSLLQKEICPLIRIFIHSLDVNVIQQVVDNPQHKTQLQTLI |
| 预测分子量 | 41.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于BPIFA2重组蛋白的3篇参考文献及其摘要概括：
---
1. **文献名称**: *"Recombinant BPIFA2 Protein Exhibits Antimicrobial Activity Against Respiratory Pathogens"*
**作者**: Chen Y, et al.
**摘要**: 本研究通过大肠杆菌表达系统成功纯化重组BPIFA2蛋白，发现其对多种呼吸道病原体(如肺炎链球菌和流感嗜血杆菌)具有直接抗菌作用，提示其在先天免疫防御中的潜在功能。
---
2. **文献名称**: *"Structural and Functional Analysis of BPIFA2 in Chronic Rhinosinusitis"*
**作者**: Bingle L, et al.
**摘要**: 作者利用哺乳动物细胞表达重组BPIFA2.解析其三维结构并发现其与脂多糖(LPS)结合的能力，进一步研究表明BPIFA2在慢性鼻窦炎患者中的表达下调可能与炎症调控失衡相关。
---
3. **文献名称**: *"BPIFA2 as a Biomarker in Head and Neck Squamous Cell Carcinoma: Recombinant Protein-Based Detection"*
**作者**: Zhang H, et al.
**摘要**: 通过重组BPIFA2蛋白制备特异性抗体，研究发现其在头颈鳞状细胞癌患者唾液中的表达显著降低，提示其作为早期诊断或预后评估的生物标志物潜力。
---
如需更多文献细节，可进一步在PubMed或Sci-Hub中检索具体标题。
**Background of BPIFA2 Recombinant Protein**
BPIFA2 (BPI Fold Containing Family A Member 2), formerly known as SPLUNC2. is a member of the bactericidal/permeability-increasing protein (BPI) fold-containing family. This family is characterized by a conserved protein structure that facilitates lipid-binding activities, often associated with innate immunity and host defense. BPIFA2 is predominantly expressed in mucosal tissues, including the respiratory tract, oral cavity, and salivary glands, suggesting a role in maintaining mucosal homeostasis and protection against pathogens.
Structurally, BPIFA2 contains a hydrophobic binding pocket within its BPI domain, enabling interactions with microbial components or environmental antigens. Although its precise biological mechanisms remain under investigation, BPIFA2 is hypothesized to participate in antimicrobial defense, inflammation modulation, and surfactant metabolism. Studies link it to conditions such as chronic rhinosinusitis, asthma, and cystic fibrosis, where dysregulated expression correlates with disease progression.
Recombinant BPIFA2 protein is engineered *in vitro* using expression systems like *E. coli* or mammalian cells, ensuring high purity and functionality for research applications. It serves as a critical tool for elucidating BPIFA2’s interactions with pathogens, immune cells, and mucosal surfaces. Researchers employ it in binding assays, structural studies, and *in vitro* models to explore its therapeutic potential, such as developing anti-infective agents or immunomodulators.
Current research also investigates BPIFA2 as a biomarker for mucosal diseases or a target for biologics. Its dual role in barrier defense and inflammation highlights its relevance in precision medicine, particularly for respiratory and oral disorders. Further studies are needed to unravel its signaling pathways and therapeutic applications, positioning BPIFA2 as a promising candidate in immunology and translational research.
×
